Tag: RevMed
ASCO26: RevMed’s daraxonrasib presents a turning point for pancreatic cancer
Pancreatic cancer stands as one of oncology’s most formidable adversaries, often diagnosed late and notoriously aggressive, leaving patients and clinicians with limited, often challenging,...



